HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.

AbstractBACKGROUND:
Human immunodeficiency virus (HIV)-infected pregnant women are at increased risk of malaria and its complications. In vitro and in vivo data suggest that the HIV protease inhibitors lopinavir/ritonavir may have potent antimalarial activity. We sought to evaluate whether lopinavir/ritonavir-based antiretroviral therapy (ART) reduced the risk of placental malaria.
METHODS:
HIV-infected, ART-naive pregnant women were enrolled between gestational weeks 12 and 28 and randomly assigned to receive lopinavir/ritonavir-based or efavirenz-based ART. Women received daily trimethoprim-sulfamethoxazole prophylaxis and insecticide-treated bed nets at enrollment and were followed up to 1 year after delivery. The primary outcome was placental malaria, defined by the detection of malaria parasites, using microscopy or polymerase chain reaction (PCR) analysis of placental blood specimens. Secondary outcomes included placental malaria, defined by histopathologic results; adverse birth outcomes; incidence of malaria; and prevalence of asymptomatic parasitemia. Analyses were done using an intention-to-treat approach.
RESULTS:
Of 389 subjects randomly assigned to a treatment group, 377 were followed through to delivery. There was no significant difference in the risk of placental malaria, as defined by thick smear or PCR findings, between the lopinavir/ritonavir-based and efavirenz-based ART arms (7.4% vs 9.8%; P = .45). Similarly, there were no differences in secondary outcomes between the 2 treatment arms.
CONCLUSIONS:
Lopinavir/ritonavir-based ART did not reduce the risk of placental or maternal malaria or improve birth outcomes, compared with efavirenz-based ART.
CLINICAL TRIALS REGISTRATION:
NCT00993031.
AuthorsPaul Natureeba, Veronica Ades, Flavia Luwedde, Julia Mwesigwa, Albert Plenty, Pius Okong, Edwin D Charlebois, Tamara D Clark, Bridget Nzarubara, Diane V Havlir, Jane Achan, Moses R Kamya, Deborah Cohan, Grant Dorsey
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 210 Issue 12 Pg. 1938-45 (Dec 15 2014) ISSN: 1537-6613 [Electronic] United States
PMID24958908 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Chemical References
  • Anti-HIV Agents
  • Antimalarials
  • Benzoxazines
  • Lopinavir
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • efavirenz
  • Ritonavir
Topics
  • Adolescent
  • Adult
  • Anti-HIV Agents (therapeutic use)
  • Antimalarials (therapeutic use)
  • Antiretroviral Therapy, Highly Active (methods)
  • Benzoxazines (therapeutic use)
  • Female
  • HIV Infections (complications, drug therapy)
  • Humans
  • Infant, Newborn
  • Lopinavir (therapeutic use)
  • Malaria (prevention & control)
  • Pregnancy
  • Pregnancy Complications, Infectious (drug therapy, prevention & control)
  • Ritonavir (therapeutic use)
  • Treatment Outcome
  • Trimethoprim, Sulfamethoxazole Drug Combination (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: